Pharvaris N.V. (PHVS) Stock Price & Analysis
Pharvaris N.V. (PHVS) closed at USD 30.68 on Thursday, October 22, 2026, up 0.07% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 30.68; the Oct 22, 2026 session ranged USD 29.85–31.02 on volume of 347,235 shares. Market capitalization is —, with a 52-week range of USD 21.02–43.25 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:27 UTC.
Also available as compact Markdown for AI agents: nexqual.com/PHVS.md
Key facts (PHVS)
- 1 of 80 tracked superinvestors hold PHVS (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
- Total return with dividends: 1Y +33.4% vs S&P 500 +14.9%; 5Y +101.2% vs S&P 500 +80.3%.
- Next earnings: 2026-11-12, EPS estimate USD -0.72, revenue estimate $0K.
Superinvestors (SEC 13F-HR, Q2 2026) (PHVS)
1 of 80 tracked investors hold PHVS. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Viking Global | Viking Global Investors | 0.36% | $126M | Unchanged |
Analysts (PHVS)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-10 | Guggenheim | Target raised | Buy | $40 → $44 |
| 2026-09-09 | Morgan Stanley | Target raised | Overweight | $46 → $62 |
| 2026-09-09 | Leerink Partners | Target raised | Outperform | $50 → $65 |
| 2026-09-09 | Wells Fargo | Target raised | Overweight | $55 → $65 |
| 2026-09-09 | RBC Capital | Target raised | Outperform | $52 → $62 |
| 2026-09-09 | Citizens | Target raised | Market Outperform | $75 → $79 |
| 2026-09-09 | Wedbush | Target raised | Outperform | $42 → $50 |
| 2026-09-08 | HC Wainwright & Co. | Reiterated | Buy | $60 |
| 2026-09-08 | Wedbush | Reiterated | Outperform | $42 |
| 2026-08-13 | RBC Capital | Target raised | Outperform | $51 → $52 |
| 2026-08-13 | Guggenheim | Target raised | Buy | $39 → $40 |
| 2026-08-13 | Citizens | Target raised | Market Outperform | $74 → $75 |
Total return (dividends reinvested) (PHVS)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +33.4% | +101.2% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +33.5% | +15.0% |
| Volatility (annualized) | 53.0% | 101.2% |
| Max drawdown | -28.6% (Sep 2026→Oct 2026) | -92.8% (Jun 2022→Nov 2022) |
PHVS analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.72 | $-0.66 | +8.9% | $0 | 11 |
| Next quarter (ends Dec 2026) | $-0.77 | $-0.70 | +9.5% | $0 | 11 |
| Current fiscal year (ends Dec 2026) | $-2.77 | $-2.62 | +5.9% | $0 | 13 |
| Next fiscal year (ends Dec 2027) | $-2.72 | $-2.35 | +15.8% | $32.2M | 12 |
Key Statistics (as of October 23, 2026 at 09:27 UTC)
| Price | USD 30.68 |
|---|---|
| Change | ▲ 0.07% (up) |
| Previous Close | USD 30.68 |
| Open | USD 30.68 |
| Day Range | USD 29.85 – 31.02 |
| 52-Week Range | USD 21.02 – 43.25 |
| Volume | 347,235 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (PHVS)
Nexqual's technical model rates PHVS "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 09:27 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 44.79 (neutral) |
| vs SMA50 | Below (USD 34.03) |
| MACD | -1.14 (negative) |
Earnings (PHVS)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD -0.72 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.7 vs est -0.65 ▼ miss |
| 2025-12-31 | USD -0.71 vs est -0.62 ▼ miss |
| 2025-09-30 | USD -0.6 vs est -0.67 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Financials & Fundamentals (PHVS)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -70.46% |
| Debt / Equity | 0 |
| Current Ratio | 11.94 |
| Total Cash | $318.28M |
| Total Debt | $673,728 |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Ownership (PHVS)
| Insider Ownership | +6.32% |
|---|---|
| Institutional Ownership | +93.40% |
| Shares Outstanding | 70.20M |
| Float | 44.13M |
| Short % of Float | +3.47% |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| EWTX | Edgewise Therapeutics, Inc. | USD 39.99 | ▲ 0.86% |
| CGEM | Cullinan Therapeutics, Inc. | USD 14.92 | ▲ 0.2% |
| IMCR | Immunocore Holdings plc | USD 32.12 | ▲ 0.09% |
| ORIC | Oric Pharmaceuticals, Inc. | USD 13.63 | ▼ 1.59% |
| TYRA | Tyra Biosciences, Inc. | USD 20.87 | ▲ 1.31% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:27 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt